For research use only. Not for therapeutic Use.
DUPA, belongs to a class of glutamate ureas, is used as the targeting moiety in agent conjugate to selectively deliver cytotoxic agents to prostate cancer cells[1][2].
DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of prostate-specific membrane antigen (PSMA) expressing prostate cancer[1]. The DUPA-indenoisoquinoline conjugate exhibits an IC50 in the low nanomolar range in 22RV1 cell cultures[2].
The DUPA-indenoisoquinoline conjugate induces a complete cessation of tumor growth with no toxicity, as determined by loss of body weight and death of treated mice[2].
| Catalog Number | I019274 |
| CAS Number | 302941-52-2 |
| Synonyms | (2S)-2-[[(1S)-1,3-dicarboxypropyl]carbamoylamino]pentanedioic acid |
| Molecular Formula | C11H16N2O9 |
| Purity | ≥95% |
| InChI | InChI=1S/C11H16N2O9/c14-7(15)3-1-5(9(18)19)12-11(22)13-6(10(20)21)2-4-8(16)17/h5-6H,1-4H2,(H,14,15)(H,16,17)(H,18,19)(H,20,21)(H2,12,13,22)/t5-,6-/m0/s1 |
| InChIKey | SOAPXKSPJAZNGO-WDSKDSINSA-N |
| SMILES | C(CC(=O)O)C(C(=O)O)NC(=O)NC(CCC(=O)O)C(=O)O |
| Reference | [1]. Peng ZH, et al. Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer. J Drug Target. 2013 Dec;21(10):968-80. [2]. Roy J, et al. DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selective prostate cancer cell targeting. J Med Chem. 2015 Apr 9;58(7):3094-103. |
